HealthCentral acquires Wellsphere

Share this article:
HealthCentral acquires Wellsphere
HealthCentral acquires Wellsphere

HealthCentral has acquired Wellsphere, a health and wellness information and technology firm. Wellsphere will add close to four million unique viewers per month to HealthCentral's network of properties. Terms of the deal were not disclosed.

Wellsphere brings an aggregated 1,500 health and wellness bloggers into the fold, in addition to its “Health Knowledge Engine” which identifies and organizes related health content for consumers, according to Jeremy Shane, president and COO at HealthCentral.

Wellsphere's bloggers may be monetized through the placement of banners and other advertising, said Shane, but the bloggers will also deliver “access to an audience of influentials, that can potentially redistribute HealthCentral's messaging.”

In that capacity, a stable of bloggers would complement HealthCentral's professional writers, whose medically reviewed columns drive content, and carry banner inventory for pharmas, explained Shane. Wellsphere's organizational technology deciphers specific content and serves it to consumers, pairing individual inquiries with longtail health information for actionable results, he said.

Additionally, Wellsphere has developed a series of consumer tools such as “Wellphone,” a mobile platform, “WellPages,” a personalized account service and “Wellternatives,” a tool that provides nutritional information about menus from restaurants across the country.

With the addition of four million unique viewers (UV) per month, HealthCentral's network of properties could reach nearly 10 million UV in the coming months. However, Shane says UV count isn't everything. “It's about performance of scale, not ‘the biggest is the best.' That's the game,” he said.

HealthCentral's title property, healthcentral.com, is one of over 30 condition-specific websites owned by the company.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.